Date: Monday, November 6, 2017
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in severe joint
damage and physical disability, therefore, the discovery of new marker(s) for joint
destruction is needed. Serum 14-3-3η protein is a novel diagnostic marker for RA, and
also involved in joint damage (1, 2). 14-3-3η protein has been reported to be expressed at
significantly higher levels in synovial fluid (SF) of RA patients when compared with
matched serum by immunoblot analysis (1). Correlation of serum 14-3-3η protein with
clinical variables, autoantibodies, inflammatory markers, and radiologic damage has
been examined in RA (2). These associations have never been examined for RA
synovial fluid (SF) 14-3-3η protein. In this study, we quantified SF 14-3-3η by ELISA
and determined the association of serum and SF14-3-3η protein with clinical, laboratory
and radiographic damage in RA.
RA patients diagnosed according to 2010 ACR criteria were included. Serum and SF
samples were obtained from all patients at the same day and 14-3-3η protein levels
were measured using the quantitative 14-3-3η ELISA kit (Augurex Life Sciences Corp).
A 14-3-3η cut-off of ≥ 0.19 ng/ml, the diagnostic cut-off was employed. Radiological
damage was evaluated using Sharp/van der Heijde score (SHS). Spearman or Pearson
correlations to compare relationships and Mann-Whitney U test for groups difference
were used for statistical analysis.
A total of 39 RA patients, mean age of 38 years, with 87.2% being female were
included. Their mean disease duration was 9.3 years, and 48.7% of patients had
moderate DAS28. Mean SF14-3-3η protein levels were 2 fold higher than mean serum
protein levels (3.7 vs 1.7 ng/ ml). The prevalence of 14-3-3η protein positivity was
higher in SF compared with serum from RA patients; 82.1% versus 69.2%, respectively.
Although there was significant correlation between SF 14-3-3η protein levels and ESR
(p=0.036), no significant association was found between serum or SF 14-3-3η protein
levels with DAS28 or autoantibodies in RA. There was significant correlation between
serum and SF 14-3-3η protein levels (p<0.05) in RA patients. Serum and SF 14-3-3η
protein levels were positively correlated with SHS (p<0.001). RA patients who were
serum or SF 14-3-3η protein positive showed significant difference in SHS but not in
clinical and laboratory features when compared with 14-3-3η negative patients.
14-3-3η levels are significantly higher in SF than in matched serum. Serum and SF14-3-
3η protein levels correlate with radiographic damage. This study further substantiates
14-3-3η as a mechanistic joint damage marker for RA.
1. Kilani et al. J Rheumatology 2007, 34 (8).
2. Maksymowych et al. Arthritis Research Therapy 2014,16: R99.
To cite this abstract in AMA style:Hammam N, Salah S, Marotta A, F. Kholef E. Evaluation of Synovial Fluid 14-3-3η Protein As a Marker of Joint Damage in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-synovial-fluid-14-3-3%ce%b7-protein-as-a-marker-of-joint-damage-in-rheumatoid-arthritis-patients/. Accessed August 13, 2020.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-synovial-fluid-14-3-3%ce%b7-protein-as-a-marker-of-joint-damage-in-rheumatoid-arthritis-patients/